

Increasing incidence of *Clostridium difficile* infections: results from a 5-year retrospective study in a large teaching hospital in the Italian region with the oldest population

C. ALICINO¹, D. R. GIACOBBE^{1,2*}, P. DURANDO^{1,3}, D. BELLINA⁴,
A. M. DI BELLA⁴, C. PAGANINO¹, V. DEL BONO², C. VISCOLI^{1,2},
G. ICARDI^{1,4} AND A. ORSI^{1,4}

¹ Department of Health Sciences, University of Genoa, Genoa, Italy

² Infectious Diseases Unit, IRCCS University Hospital San Martino–IST National Institute for Cancer Research, Genoa, Italy

³ Occupational Medicine Unit, IRCCS University Hospital San Martino–IST National Institute for Cancer Research, Genoa, Italy

⁴ Hygiene and Infection Control Unit, IRCCS University Hospital San Martino–IST National Institute for Cancer Research, Genoa, Italy

Received 29 February 2016; Final revision 19 April 2016; Accepted 19 April 2016;
first published online 19 May 2016

SUMMARY

Limited information is available on the incidence of *Clostridium difficile* infections (CDIs) in Italian hospitals. In this study, we assessed the changes in the incidence of CDI over a 5-year period in a teaching hospital in Liguria, the Italian region with the oldest population. Secondary endpoints were the development of severe CDI and 30-day mortality. The annual incidence of CDI/10000 patient-days significantly increased from 0·54 in 2010 to 3·04 in 2014 (χ^2 for trend, $P < 0\cdot001$). The median age of patients with CDI was 81 years. As many as 81% and 89% of these patients had comorbid conditions and previous exposure to antibiotics, respectively. In the multivariate analysis of risk factors for severe CDI, previous therapy with histamine 2 blockers and low serum albumin were associated with severe CDI, while diabetes appeared to be protective. In the multivariate model of risk factors for 30-day mortality, high leukocyte count, low serum albumin, and increased serum creatinine were unfavourably associated with outcome. Strict adherence to infection control measures was of utmost importance to counteract the increasing incidence of CDI in our hospital, particularly because of the advanced age of the patients and their very high frequency of chronic conditions and use of antibiotics, which readily predispose them to the development of CDI.

Key words: *Clostridium difficile*, healthcare-associated infections, hospital-acquired infections, incidence, mortality.

INTRODUCTION

Clostridium difficile is the major cause of hospital-acquired infectious diarrhoea and one of the most

common pathogens responsible for healthcare-associated infections [1]. Over the past decades, a marked increase in the incidence of *C. difficile* infections (CDIs) has been reported from different countries and continents [2–4]. In the United States, CDI hospitalizations/10000 population increased from 3·1 cases in 1996 to 6·1 in 2003, and from 5·5 cases in 2000 to 11·2 in 2005 [5, 6]. A similar epidemiological picture has been observed in Europe [7–9].

* Author for correspondence: D. R. Giacobbe, MD, IRCCS University Hospital San Martino–IST National Institute for Cancer Research, Infectious Diseases Unit, L. go R. Benzi 10-16132, Genoa, Italy.
(Email: daniele.roberto.giacobbe@gmail.com)

In recent years, a relative increase in the number of severe cases of CDI has also been registered, possibly related to the increased use of wide-spectrum antibiotics and the emergence and spread of hypervirulent strains [2, 10–12].

To reduce both the incidence of CDI and the proportion of severe cases the supranational data cited above should be considered together with the detailed epidemiology of every single hospital, aiming at identifying the most cost-effective measures to be used locally. As the first step in this process, we assessed the changes in the incidence of CDI over a 5-year period in a large teaching hospital in Liguria (the Italian region with the oldest population [13]), as well as the risk factors for developing severe disease and for dying within 30 days of infection.

METHODS

Setting and definitions

We carried out a retrospective study at IRCCS AOU San Martino–IST, a 1300-bed tertiary adult acute-care teaching hospital in Genoa, Liguria Region, Italy. From 1 January 2010 to 31 December 2014, all patients with hospital-acquired CDI were identified through the hospital laboratory database.

A CDI episode was defined as the presence of at least one unformed stool specimen positive for *C. difficile* toxin A and/or B (C. Diff Quick Chek complete[®], Techlab, USA; Alere Medical Co. Ltd, USA), according to the National Health Safety Network (NHSN) definition [14]. For the purpose of the study, recurrences of disease (new episodes occurring within 56 days after the first positive sample) were excluded from the analyses [14]. A CDI episode was defined as hospital-acquired if occurring >3 days after hospitalization, or within 28 days after discharge [14].

A CDI episode was classified as severe if fulfilling at least one of the following criteria: (i) death within 14 days after the onset of symptoms; (ii) requirement of intensive care unit (ICU) admission; (iii) requirement of colectomy or other surgery procedures; (iv) intestinal perforation [15, 16].

Study endpoints

The primary endpoint was the incidence of CDI/10000 patient-days over the study period. Secondary endpoints were: (i) proportion of positive tested patients; (ii) proportion of severe cases; (iii) development of severe CDI; (iv) 30-day all-cause mortality.

Data collection

For the computation of the annual incidences of CDI, the overall number of hospital patient-days was obtained from the hospital digital archives of patients' clinical charts.

For the assessment of risk factors for severe disease and mortality, the following data were collected from the medical records of patients with CDI: age; gender; baseline comorbidities (congestive heart failure, myocardial infarction, chronic obstructive pulmonary disease, cerebrovascular accident, solid malignancy, haematological malignancy, diabetes mellitus, chronic renal failure); Charlson comorbidity index score [17]; chronic haemodialysis; previous surgery (within 3 months); previous ICU stay (within 3 months); previous mechanical ventilation (within 3 months); previous therapy with antimicrobials, proton pump inhibitors, and/or histamine 2 (H2) blockers (within 8 weeks before CDI); length of hospital stay before developing CDI; other infections at the time of CDI diagnosis (defined and classified according to CDC definitions [18]); serum haemoglobin, albumin, creatinine, and leukocyte count at the time of CDI diagnosis; type of antimicrobial treatment and complications of CDI (requirement of haemodialysis, requirement of ICU admission, requirement of surgery, intestinal perforation).

Statistical analysis

Annual CDI incidence rates with their 95% confidence intervals (CIs) were calculated as the number of events/10000 patient-days. They were also stratified according to the ward where the diagnosis of CDI was made (ICU, medical ward, haemato-oncological ward, rehabilitation ward, surgical ward). A χ^2 test for linear trend was used to assess the changes in the annual incidence of CDI in our hospital over the study period, as well as the changes in the proportion of positive tested patients and severe cases.

For the assessment of risk factors for severe CDI and 30-day mortality, continuous variables were dichotomized and cut-off values were determined through receiver-operating characteristic curves. Then, demographic and clinical variables of patients with CDI were compared in univariate analyses by the χ^2 test or Fisher's exact test, as appropriate. These tests were performed for both comparisons (patients without severe CDI vs. patients with severe CDI, and survivors vs. non-survivors), all tests were

two-sided. To assess the independent role of risk factors, variables with a P value < 0.05 in univariate comparisons were included in two logistic regression models (patients without severe CDI *vs.* patients with severe CDI, and survivors *vs.* non-survivors).

Statistical analyses were performed with Epi-Info v. 7.0 (CDC, USA) and JMP v. 10.0 (SAS Institute, USA).

Ethical statement

The study was performed within the institutional surveillance of healthcare-associated infections and involved the analysis of existing anonymized clinical and laboratory data. An informed consent for the use of anonymized data for scientific purposes is signed by all patients admitted to IRCCS AOU San Martino-IST and included in surveillance databases. The study was approved by the Regional Ethics Committee of Liguria Region.

RESULTS

During the study period, we identified 388 episodes of hospital-acquired CDI. These episodes occurred in 381 patients, of whom seven experienced at least one novel episode beyond 56 days after the previous CDI (1.8%). The complete demographic and clinical characteristics of patients at the time of CDI diagnosis are summarized in Tables 1 and 2. Of note, the median age of patients was as high as 81 years [interquartile range (IQR) 74–87] and as many as 81% and 89% of the patients had comorbid conditions and previous exposure to antibiotics, respectively.

Table 3 shows that the trend in the annual incidence of CDI/10000 patient-days significantly increased from 0.54 in 2010 to 3.04 in 2014 (χ^2 for linear trend, $P < 0.001$). When the analysis was stratified according to the ward where the CDI diagnosis was made, statistically significant increases were observed in medical, haemato-oncological, and rehabilitation wards. The highest annual incidences of CDI were registered in rehabilitation wards, with a peak of 10.01 episodes/10000 patient-days in 2013. It should be noted that the proportion of positive tested patients significantly increased over the study period (χ^2 for trend, $P = 0.002$), while the proportion of severe cases apparently decreased (χ^2 for trend, $P < 0.05$).

Seventy-three of 388 CDI episodes met the criteria for severe CDI (18.8%). Results of the univariate and multivariate analyses of risk factors for severe CDI are shown in Table 4. In the univariate analysis,

age ≥ 72 years [odds ratio (OR) 2.79, 95% CI 1.31–6.93, $P = 0.007$], congestive heart failure (OR 1.98, 95% CI 1.17–3.34, $P = 0.01$), previous mechanical ventilation (OR 2.93, 95% CI 1.04–7.73, $P = 0.04$), previous therapy with H2 blockers (OR 2.15, 95% CI 1.10–4.09, $P = 0.03$), ward of stay at time of CDI diagnosis, and serum albumin ≤ 2.5 g/dl (OR 3.30, 95% CI 1.76–6.43, $P < 0.001$) were associated with the development of severe CDI, while an intriguing protective role was suggested for diabetes (OR 0.26, 95% CI 0.08–0.67, $P = 0.003$). In the multivariate analysis, previous therapy with H2 blockers (OR 2.70, 95% CI 1.13–6.38, $P = 0.03$) and serum albumin ≤ 2.5 g/l (OR 2.90, 95% CI 1.44–6.05, $P = 0.003$) remained significantly associated with the development of severe CDI, while diabetes was confirmed as a possible protective factor (OR 0.18, 95% CI 0.04–0.57, $P = 0.002$).

The all-cause 30-day mortality in patients with CDI was as high as 27.8% (108/388). In the univariate analysis of risk factors for mortality, age ≥ 72 years (OR 2.52, 95% CI 1.34–5.08, $P = 0.003$), congestive heart failure (OR 1.92, 95% CI 1.2–3.05, $P = 0.006$), previous mechanical ventilation (OR 3.47, 95% CI 1.33–9.33, $P = 0.01$), ward of stay at the time of CDI diagnosis ($P = 0.001$, with the highest risk registered for patients hospitalized in ICU wards), other infections at the time of CDI diagnosis (OR 2.30, 95% CI 1.32–3.99, $P = 0.004$), leukocyte count ≥ 20 cells $\times 10^9/l$ (OR 4.87, 95% CI 2.96–8.08, $P < 0.001$), serum albumin ≤ 2.5 g/dl (OR 3.04, 95% CI 1.75–5.39, $P < 0.001$), serum creatinine ≥ 1.6 mg/dl (OR 3.39, 95% CI 2.11–5.49, $P < 0.001$), and requirement of ICU admission (OR 16.41, 95% CI 2.76–311.9, $P = 0.01$) were unfavourably associated with outcome (see Table 5). Table 5 also shows the results of the related multivariate analysis, which confirmed the following variables as factors significantly and unfavourably associated with outcome: leukocyte count ≥ 20 cells $\times 10^9/l$ (OR 2.74, 95% CI 1.39–5.46, $P = 0.004$); serum creatinine ≥ 1.6 mg/dl (OR 1.94, 95% CI 1.0–3.79, $P < 0.05$); serum albumin ≤ 2.5 g/dl (OR 2.19, 95% CI 1.11–4.37, $P = 0.02$).

DISCUSSION

From 2010 to 2014, we observed an increase of nearly 600% in the incidence of hospital-acquired CDI in our facility, from 0.54 to 3.04 CDI episodes/10000 patient-days. These episodes mostly occurred in elderly patients, with very high rates of baseline comorbidities and previous antibiotic use.

Table 1. Demographic, anamnestic and clinical characteristics of the study population with *C. difficile* infection (CDI)

Patients' features	Patients (N = 388)	% (95% CI)
Demographic and anamnestic data		
Age, years, median (IQR)	81 (74–87)	
Gender		
Male	156	40.2 (35.3–45.3)
Female	232	59.8 (54.7–64.7)
Length of hospital stay, days, median (IQR)	40 (25.5–64)	
Length of hospital stay before CDI, days, median (IQR)	20 (11–36)	
Length of hospital stay after CDI, days, median (IQR)	15.5 (7–27.8)	
Charlson comorbidity index score, median (IQR)	2 (1–3)	
Congestive heart failure	121	31.2 (26.7–36.1)
Myocardial infarction at admission	10	2.6 (1.3–4.8)
Chronic obstructive pulmonary disease	61	15.7 (12.3–19.8)
Cerebrovascular accident	83	21.4 (17.5–25.9)
Solid malignancy	64	16.5 (13.0–20.7)
Haematological malignancy	21	5.4 (3.5–8.3)
Diabetes	61	15.7 (12.3–19.8)
Renal function		
Normal	294	75.8 (71.1–79.9)
Chronic renal insufficiency without dialysis	81	20.9 (17.0–25.3)
End-stage renal insufficiency on dialysis	13	3.3 (1.9–5.8)
Surgery prior to developing CDI		
Abdominal surgery prior to developing CDI	19	4.9 (3.1–7.7)
Mechanical ventilation prior to developing CDI	18	4.6 (2.9–7.4)
Intensive care unit admission prior to developing CDI	45	11.6 (8.7–15.3)
Medication exposures in the 8 weeks before CDI (n = 385)		
Histamine 2 blocker	52	13.5 (10.3–17.4)
Proton pump inhibitor	334	86.8 (82.9–89.9)
Any antibiotic exposure	343	89.1 (85.4–91.9)
Number of antibiotics, median (IQR)		
Fluoroquinolones	185	48.1 (43.0–53.2)
β -lactam/ β -lactamase inhibitors	152	39.5 (34.6–44.6)
3rd-generation cephalosporins	129	33.5 (28.9–38.5)
Carbapenems	66	17.1 (13.6–21.4)
Glycopeptides	51	13.3 (10.1–17.1)
Metronidazole	29	7.5 (5.2–10.8)
Macrolides	24	6.2 (4.1–9.3)
Aminoglycosides	12	3.1 (1.7–5.5)
Oxazolidinone	11	2.9 (1.5–5.2)
Trimethoprim-sulfamethoxazole	5	1.3 (0.5–3.2)
4th-generation cephalosporins	4	1.0 (0.3–2.8)
Daptomicin	3	0.8 (0.2–2.5)
Colistin	1	0.3 (0.01–1.7)
Penicillin G	1	0.3 (0.01–1.7)

CI, Confidence interval; IQR, interquartile range.

Limited information is available on the incidence of CDI in Italian hospitals [19, 20]. Our results are consistent with those of Di Bella and colleagues, who reported an increased incidence of CDI, from 0.3 cases in 2006 to 2.3 cases/10000 patient-days in 2011 in five hospitals in Rome [19]. Similarly, Bassetti *et al.* observed an increase in the incidence of CDI

from 1.7 cases/10000 patient-days in 2009 to 3.0 cases in 2012 in a teaching hospital in Udine [20]. As in our research, the results of Di Bella *et al.* and Bassetti *et al.* relied on enzyme immunoassay (EIA) tests. Importantly, the change in the incidence of CDI in these studies might have been overestimated because of the increase in the number of tested

Table 2. Clinical characteristics, therapeutic management and outcomes of *C. difficile* infections (CDI)

Clinical characteristics and therapeutic management of CDI	Patients (N = 388)	% (95% CI)
Ward of admission at onset of CDI		
Intensive care	11	2.9 (1.5–5.2)
Medical	198	51.0 (45.9–56.1)
Haemato-oncological	27	7.0 (4.7–10.1)
Rehabilitation	134	34.5 (29.9–39.5)
Surgical	18	4.6 (2.9–7.4)
Infection concomitant to CDI*	65	16.8 (13.3–20.9)
Bloodstream infection concomitant to CDI	36	9.3 (6.7–12.7)
Leukocyte (cells × 10 ⁹ /l), median (IQR) (n = 376)	13.8 (9–20.1)	
Haemoglobin (g/dl), median (IQR) (n = 376)	10.1 (8.9–11.4)	
Albumin (g/dl), median (IQR) (n = 243)	2.5 (2.1–2.9)	
Creatinine (mg/dl), median (IQR) (n = 373)	1.1 (0.7–1.8)	
Therapeutic management (n = 386)		
No therapy	15	3.9 (2.3–6.5)
Vancomycin (oral)	261	67.6 (62.6–72.2)
Metronidazole (intravenous or oral)	77	19.9 (16.2–24.4)
Vancomycin (oral) and metronidazole (intravenous or oral)	33	8.6 (6.0–11.9)
Outcome of CDI		
Intensive care unit admission	7	1.8 (0.8–3.9)
Abdominal surgery	1	0.3 (0.01–1.7)
Recurrence within 54 days	30	7.7 (5.4–11.0)
Development of severe CDI	73	18.8 (15.2–23.1)
30-day all-cause mortality	108	27.8 (23.4–32.6)

CI, Confidence interval; IQR, interquartile range.

* Bloodstream = 36 (55.4%); urinary tract = 21 (32.3%); lower respiratory tract = 7 (10.7%); surgical site = 1 (1.6%).

patients over years [19, 20]. Although this bias was also present in our study, the simultaneous increase in the proportion of positive tested patients over the study period seems to confirm the role of *C. difficile* as an important and increasing cause of healthcare-associated diarrhoea. Of note, any change in CDI incidence due to reduced or enhanced adherence to infection-control practices appears unlikely to have occurred, since routine audits to guarantee a high level of compliance were performed in our hospital during the whole study period.

With regard to single departments, it should be noted that in our study the highest peaks in CDI incidence were registered in rehabilitation wards. This possibly occurred because of the high median age, median length of stay, and rate of previous exposure to antimicrobials of patients hospitalized in these wards (they were indeed mostly transferred to the rehabilitation unit after acute care in medical or ICU wards), all well-recognized risk factors for the development of the disease [21]. However, it should also be noted that the overall median age of patients with CDI in the entire hospital was as high as 81 years. To the best of our

knowledge, this is the highest median age observed in similar research, and it is probably related to the demographic characteristics of the population in the hospital catchment area [13]. Other important aspects worth reporting are the high frequency of baseline comorbidities (80.7% of patients with CDI had at least one chronic condition) and that the overall rate of previous use of antibiotics (mostly fluoroquinolones, β -lactam/ β -lactamases inhibitor combinations, and third-generation cephalosporins) was as high as 89.1% in our cohort of CDI patients, among the highest reported in the literature [20, 22, 23].

As many as 18.8% of episodes were considered as severe CDI, in line with rates reported by others [24]. Of note, several variables associated with the development of severe CDI (i.e. prior acid suppression, baseline serum albumin ≤ 2.5 g/dl) have already been described by other authors, and testify to the role of concomitant medications and nutritional status in influencing the course of the disease, as well as to the possible protective effect exerted by albumin [24, 25]. On the other hand, diabetes was apparently protective against severe CDI in our cohort. This result

Table 3. Number of samples and patients tested (total and proportion positive) per year and annual incidences of hospital-acquired *C. difficile* infections (CDI) in IRCCS AOU San Martino-IST of Genoa, Italy

Year	No. of tested samples	No. of CDI episodes	No. of severe CDI episodes (%)	No. of unique patients with CDI	Positive patients/ tested patients (%)	Incidence/10000 patient-days (95% CI) (ward where the diagnosis of CDI was made)					
						Overall	ICU wards	Medical wards	Hemato-oncological wards	Rehabilitation wards	Surgical wards
2010	289	19	7/19 (36.8)	19	19/227 (8.4)	0.54 (0.35-0.85)	2.38 (0.77-7.37)	0.49 (0.24-0.97)	0.44 (0.06-3.15)	2.26 (0.85-6.03)	0.32 (0.10-0.99)
2011	455	32	5/32 (15.6)	32	32/375 (8.5)	0.66 (0.47-0.93)	-	1.12 (0.75-1.67)	0.28 (0.04-1.96)	1.80 (0.81-4.00)	0.08 (0.01-0.54)
2012	700	74	17/74 (23.0)	74	74/551 (13.4)	1.56 (1.24-1.96)	1.69 (0.55-5.25)	2.04 (1.51-2.76)	2.01 (0.96-4.21)	4.40 (2.84-6.82)	0.16 (0.04-0.65)
2013	1156	127	21/127 (16.5)	125	125/801 (15.6)	2.76 (2.32-3.28)	2.14 (0.80-5.69)	2.68 (2.04-3.53)	1.20 (0.45-3.19)	10.01 (7.82-12.81)	0.44 (0.18-1.05)
2014	1352	136	23/136 (16.9)	131	131/937 (14.0)	3.04 (2.57-3.60)	0.51 (0.07-3.61)	3.88 (3.09-4.88)	3.55 (2.10-5.99)	8.04 (5.92-10.92)	0.66 (0.31-1.37)
χ^2 for trend (P value)	-	-	<0.05	-	0.002	<0.001	0.61	<0.001	0.001	<0.001	0.05

CI, Confidence interval.

might be explained by the fact that diabetes treatment with metformin might have a protective effect against the development of CDI, according to some literature data [26]. However, this association has not been confirmed by other researchers, who conversely reported a harmful association between diabetes and CDI, thus this warrants further investigation [27].

The 30-day all-cause mortality registered in our study (27.8%) is consistent with rates reported in the literature [24]. However, we did not register any of the well-known associations between mortality and age, and between mortality and underlying comorbidities (e.g. malignancy, chronic renal failure, etc.) [24]. This is possibly related to the advanced age and the high frequency of chronic conditions in our study population. As regards laboratory variables, we found that a baseline serum leukocyte cell count $\geq 20 \times 10^9/l$, a baseline serum albumin level ≤ 2.5 g/dl, and a serum creatinine level ≥ 1.6 mg/dl were associated with increased mortality, in accord with previous studies [24]. This is consistent with the association of unfavourable outcome of CDI and altered laboratory values, conceivably indicating a severe course of the disease [24].

The present study has some limitations. First, this was a single-centre study, and our results might not be reproducible in other Italian hospitals. In addition, under-reporting possibly occurred in some cases because of the retrospective nature of the study. Another major limitation is the lack of molecular typing data. Indeed, despite an intriguing decrease in the proportion of severe cases observed over the years, the absence of molecular data prevented us from assessing whether this was associated with any possible change in the proportion of hypervirulent strains in our institution during the study period, or if other factors might perhaps better explain these findings. Finally, we were not able to retrospectively conduct a reliable in-depth analysis of possible changes in the type of antibiotics prescribed in our hospital during the study period.

In conclusion, from 2010 to 2014 we observed a marked increase in the incidence of hospital-acquired CDI, highlighting the need for more efficacious preventive interventions, focused on strict adherence to infection control measures and on appropriate antibiotic use. This is of the utmost importance in our hospital, because of the advanced age of our patients and their very high frequency of chronic conditions and use of antibiotics, which readily predispose them to the development of hospital-acquired CDI.

Table 4. Association between severe *C. difficile* infection (CDI) and potential independent variables: results of univariate and multivariate logistic regression

Variables	Severe cases	Non-severe cases	Univariate analysis		Multivariate analysis	
	(N = 73) n (%)	(N = 315) n (%)	OR (95% CI)	P value	OR (95% CI)	P value
Age ≥ 72 years	66 (90.4)	243 (77.1)	2.79 (1.31–6.93)	0.007	2.11 (0.80–6.28)	0.13
Gender, male	32 (43.8)	124 (39.4)	1.20 (0.72–2.00)	0.48		
Length of hospital stay before CDI, days, median (IQR)	19 (11–40)	20 (11–35)	1.0 (0.99–1.01)	0.68		
Charlson comorbidity index score ≥ 2	44 (60.3)	170 (54.0)	1.29 (0.77–2.19)	0.33		
Congestive heart failure	32 (43.8)	89 (28.3)	1.98 (1.17–3.34)	0.01	1.96 (0.95–4.03)	0.07
Myocardial infarction at admission	4 (5.5)	6 (1.9)	2.99 (0.75–10.73)	0.12		
Chronic obstructive pulmonary disease	10 (13.7)	51 (16.2)	0.82 (0.38–1.65)	0.59		
Cerebrovascular accident	17 (23.3)	66 (21.0)	1.14 (0.61–2.07)	0.66		
Solid malignancy	15 (20.6)	49 (15.6)	1.40 (0.71–2.63)	0.31		
Haematological malignancy	5 (6.9)	16 (5.1)	1.37 (0.44–3.65)	0.56		
Diabetes	4 (5.5)	57 (18.1)	0.26 (0.08–0.67)	0.003	0.18 (0.04–0.57)	0.002*
Renal function				0.54		
Normal	53 (72.6)	241 (79.5)	Reference			
Chronic renal insufficiency without dialysis	16 (21.9)	65 (20.6)	1.12 (0.59–2.05)			
End-stage renal insufficiency on dialysis	4 (5.5)	9 (3.0)	2.02 (0.53–6.46)			
Surgery prior to developing CDI	13 (17.8)	62 (19.7)	0.88 (0.44–1.67)	0.71		
Abdominal surgery prior to developing CDI	1 (1.4)	18 (5.7)	0.23 (0.01–1.14)	0.08		
Mechanical ventilation prior to developing CDI	7 (9.6)	11 (3.5)	2.93 (1.04–7.73)	0.04	2.25 (0.40–10.58)	0.33
Intensive care unit admission prior to developing CDI	12 (16.4)	33 (10.5)	1.68 (0.79–3.36)	0.17		
Histamine 2 blocker exposure	16 (21.9)	36 (11.5)	2.15 (1.10–4.09)	0.03	2.70 (1.13–6.38)	0.03*
Proton pump inhibitor exposure	62 (84.9)	272 (87.2)	0.83 (0.41–1.78)	0.62		
Any antibiotic exposure	65 (89.0)	278 (89.1)	0.99 (0.46–2.40)	0.99		
Number of antibiotics, median (IQR)	2 (1–3)	2 (1–3)	1.05 (0.84–1.30)	0.68		
Previous fluoroquinolones	35 (48.0)	150 (48.1)	0.99 (0.60–1.66)	0.98		
Previous β-lactam/β-lactamase inhibitor combinations	29 (39.7)	123 (39.4)	1.01 (0.60–1.70)	0.96		
Previous 3rd-generation cephalosporins	22 (30.1)	107 (34.3)	0.83 (0.47–1.42)	0.50		
Previous carbapenems	16 (21.9)	50 (16.0)	1.47 (0.76–2.72)	0.24		
Previous glycopeptides	9 (12.3)	42 (13.5)	0.90 (0.40–1.87)	0.80		
Previous metronidazole	5 (6.9)	24 (7.7)	0.88 (0.29–2.22)	0.80		
Previous macrolides	6 (8.2)	18 (5.8)	1.46 (0.51–3.64)	0.45		
Previous aminoglycosides	1 (1.4)	11 (3.5)	0.38 (0.02–2.00)	0.38		
Previous oxazolidinones	4 (5.4)	7 (2.2)	2.53 (0.65–8.60)	0.17		
Previous trimethoprim/sulfamethoxazole	1 (1.4)	4 (1.3)	1.07 (0.05–7.36)	0.95		
Previous daptomycin	0 (0.0)	3 (1.0)	–			
Ward of admission at onset of CDI				<0.001		0.24
Surgical	3 (4.1)	15 (4.8)	Reference		Reference	
Intensive care	8 (11.0)	3 (1.0)	13.33 (2.44–98.99)		7.46 (0.95–76.80)	
Medical	44 (60.2)	154 (48.9)	1.43 (0.45–6.36)		1.61 (0.42–7.90)	
Haemato-oncological	4 (5.5)	23 (7.3)	0.87 (0.17–4.93)		1.24 (0.18–8.32)	
Rehabilitation	14 (19.2)	120 (38.1)	0.58 (0.17–2.73)		1.06 (0.23–5.77)	
Infection concomitant to CDI	18 (24.7)	47 (14.9)	1.87 (0.99–3.41)	0.05		
Bloodstream infection concomitant to CDI	9 (12.3)	27 (8.6)	1.50 (0.64–3.23)	0.33		
Haemoglobin ≤ 10.0 g/dl	41 (56.2)	138 (45.5)	1.53 (0.92–2.58)	0.10		
Albumin ≤ 2.5 g/dl	42 (72.4)	82 (44.3)	3.30 (1.76–6.43)	<0.001	2.90 (1.44–6.05)	0.003*

OR, Odds ratio; CI, confidence interval; IQR, interquartile range.

* Statistically significant ($P < 0.05$).

Table 5. Association between 30-day all-cause mortality of *C. difficile* infection (CDI) and potential independent variables: results of univariate and multivariate logistic regression

Variables	Survivors (N = 280) n (%)	Non-survivors (N = 108) n (%)	Univariate analysis		Multivariate analysis	
			OR (95% CI)	P value	OR (95% CI)	P value
Age ≥ 72 years	213 (76.1)	96 (88.9)	2.52 (1.34–5.08)	0.003	2.27 (0.92–6.04)	0.08
Gender, male	111 (39.6)	45 (41.7)	1.09 (0.69–1.71)	0.72		
Length of hospital stay before CDI, days, median (IQR)	20 (11–36)	19 (11–39)	1.00 (0.99–1.01)	0.65		
Charlson comorbidity index score ≥ 2	146 (52.1)	68 (63.0)	1.56 (0.99–2.47)	0.06		
Congestive heart failure	76 (27.1)	45 (41.7)	1.92 (1.2–3.05)	0.006	1.48 (0.73–3.01)	0.27
Myocardial infarction at admission	6 (2.1)	4 (3.7)	1.76 (0.44–6.27)	0.40		
Chronic obstructive pulmonary disease	44 (15.7)	17 (15.7)	1.00 (0.53–1.81)	0.99		
Cerebrovascular accident	61 (21.8)	22 (20.4)	0.92 (0.52–1.57)	0.76		
Solid malignancy	43 (15.4)	21 (19.4)	1.33 (0.74–2.35)	0.34		
Haematological malignancy	13 (4.6)	8 (7.4)	1.64 (0.63–4.02)	0.30		
Diabetes	47 (16.8)	14 (13.0)	0.74 (0.38–1.37)	0.35		
Renal function				0.11		
Normal	217 (77.5)	77 (71.3)	Reference			
Chronic renal insufficiency without dialysis	57 (20.4)	24 (22.2)	1.19 (0.68–2.02)			
End-stage renal insufficiency on dialysis	6 (2.1)	7 (6.5)	3.29 (1.06–10.50)			
Previous surgery	56 (20.0)	19 (17.6)	0.85 (0.47–1.50)	0.59		
Previous abdominal surgery	17 (6.1)	2 (1.9)	0.29 (0.05–1.04)	0.06		
Previous mechanical ventilation	8 (2.9)	10 (9.3)	3.47 (1.33–9.33)	0.01	4.83 (0.92–25.19)	0.06
Previous ICU admission	27 (9.6)	18 (16.7)	1.87 (0.97–3.54)	0.06		
Histamine 2 blocker exposure	32 (11.6)	20 (18.5)	1.74 (0.93–3.18)	0.08		
Proton pump inhibitor exposure	243 (87.7)	91 (84.2)	0.75 (0.40–1.43)	0.37		
Any previous antibiotic exposure	245 (88.5)	98 (90.7)	1.28 (0.63–2.84)	0.51		
Number of antibiotics, median (IQR)	2 (1–3)	2 (1–3)	1.12 (0.93–1.35)	0.24		
Previous fluoroquinolones	135 (48.7)	50 (46.3)	0.91 (0.58–1.42)	0.67		
Previous β-lactam/β-lactamase inhibitor combinations	108 (39.0)	44 (40.7)	1.08 (0.68–1.69)	0.75		
Previous 3rd-generation cephalosporins	91 (32.9)	38 (35.2)	1.11 (0.69–1.77)	0.66		
Previous carbapenems	43 (15.5)	23 (21.3)	1.47 (0.83–2.57)	0.18		
Previous glycopeptides	37 (13.4)	14 (13.0)	0.97 (0.49–1.83)	0.92		
Previous metronidazole	21 (7.6)	8 (7.4)	0.98 (0.39–2.19)	0.95		
Previous macrolides	15 (5.4)	9 (8.3)	1.59 (0.65–3.69)	0.30		
Previous aminoglycosides	9 (3.3)	3 (2.8)	0.85 (0.19–2.92)	0.80		
Previous oxazolidinones	6 (2.2)	5 (4.6)	2.19 (0.62–7.43)	0.21		
Previous trimethoprim/sulfamethoxazole	3 (1.1)	2 (1.9)	1.72 (0.22–10.53)	0.57		
Previous daptomycin	1 (0.4)	2 (1.9)	5.20 (0.49–112.7)	0.16		
Ward of admission at onset of CDI				0.001		0.26
Surgical	15 (5.4)	3 (2.8)	Reference		Reference	
Intensive care	3 (1.1)	8 (7.4)	13.33 (2.44–98.99)		6.17 (0.59–86.76)	
Medical	134 (47.9)	64 (59.2)	2.39 (0.75–10.57)		4.59 (0.97–34.92)	
Haemato-oncological	20 (7.1)	7 (6.5)	1.75 (0.41–9.17)		8.27 (1.21–80.39)	
Rehabilitation	108 (38.6)	26 (24.1)	1.20 (0.36–5.47)		4.14 (0.76–34.55)	
Intensive care unit admission after CDI diagnosis	1 (0.4)	6 (5.6)	16.41 (2.76–311.9)	0.001	9.07 (0.92–256.79)	0.06
Infection concomitant to CDI	37 (13.2)	28 (25.9)	2.30 (1.32–3.99)	0.004	2.15 (0.97–4.78)	0.06

Table 5 (cont.)

Variables	Survivors	Non-survivors	Univariate analysis		Multivariate analysis	
	(N = 280) n (%)	(N = 108) n (%)	OR (95% CI)	P value	OR (95% CI)	P value
Bloodstream infection concomitant to CDI	21 (7.5)	15 (13.9)	1.99 (0.97–4.0)	0.06		
Leukocyte count ≥ 20 cells $\times 10^9/l$	44 (16.2)	51 (48.6)	4.87 (2.96–8.08)	<0.001	2.74 (1.39–5.46)	0.004*
Haemoglobin ≤ 10.0 g/dl	123 (45.4)	56 (53.3)	1.38 (0.88–2.17)	0.17		
Albumin ≤ 2.5 g/dl	67 (41.9)	57 (68.7)	3.04 (1.75–5.39)	<0.001	2.19 (1.11–4.37)	0.02*
Creatinine ≥ 1.6 mg/dl	59 (22.1)	52 (49.1)	3.39 (2.11–5.49)	<0.001	1.94 (1.0–3.79)	0.05*
Therapeutic management				0.02		0.76
No therapy	6 (2.2)	9 (8.3)	Reference		Reference	
Vancomycin (oral)	197 (70.9)	64 (59.3)	0.22 (0.07–0.62)		0.89 (0.23–3.4)	
Metronidazole (intravenous or oral)	51 (18.4)	26 (24.1)	0.34 (0.10–1.04)		1.41 (0.32–6.29)	
Vancomycin (oral) and metronidazole (intravenous or oral)	24 (8.6)	9 (8.3)	0.25 (0.07–0.88)		0.85 (0.16–4.4)	

OR, Odds ratio; CI, confidence interval; IQR, interquartile range.

* Statistically significant ($P < 0.05$).

ACKNOWLEDGEMENTS

The authors thank Monica Zacconi for assistance with data collection.

DECLARATION OF INTEREST

None.

REFERENCES

- Rupnik M, Wilcox MH, Gerding DN. *Clostridium difficile* infection: new developments in epidemiology and pathogenesis. *Nature Reviews Microbiology* 2009; **7**: 526–536.
- Freeman J, et al. The changing epidemiology of *Clostridium difficile* infections. *Clinical Microbiology Reviews* 2010; **23**: 529–549.
- Johnson S. Changing epidemiology of *Clostridium difficile* and emergence of new virulent strains. *Clinical Infectious Diseases* 2014; **58**: 1731–1733.
- Lessa FC, Gould CV, McDonald LC. Current status of *Clostridium difficile* infection epidemiology. *Clinical Infectious Diseases* 2012; **55**: s65–70.
- McDonald LC, Owings M, Jernigan DB. *Clostridium difficile* infection in patients discharged from US short-stay hospitals, 1996–2003. *Emerging Infectious Diseases* 2006; **12**: 409–115.
- Zilberberg MD, Shorr AF, Kollef MH. Increase in adult *Clostridium difficile*-related hospitalizations and case-fatality rate, United States, 2000–2005. *Emerging Infectious Diseases* 2008; **14**: 929–931.
- Asensio A, et al. Increasing rates in *Clostridium difficile* infection (CDI) among hospitalised patients, Spain 1999–2007. *Eurosurveillance* 2008; **13**: 18943.
- Bauer MP, et al. *Clostridium difficile* infection in Europe: a hospital-based survey. *Lancet* 2011; **377**: 63–73.
- Burckhardt F, et al. *Clostridium difficile* surveillance trends, Saxony, Germany. *Emerging Infectious Diseases* 2008; **14**: 691–692.
- McDonald LC, et al. An epidemic, toxin gene-variant strain of *Clostridium difficile*. *New England Journal of Medicine* 2005; **353**: 2433–2441.
- Loo VG, et al. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *New England Journal of Medicine* 2005; **353**: 2442–2449.
- Kuijper EJ, et al. *Clostridium difficile* ribotype 027, toxinotype III, the Netherlands. *Emerging Infectious Diseases* 2006; **12**: 827–830.
- National Institute of Statistics (Istituto Nazionale di Statistica, ISTAT). ‘Noi Italia. 100 statistics to understand the country we live in’ (http://noi-italia2015.istat.it/index.php?id=6&user_100ind_pi%5Buid_categoria%5D=03&L=0&cHash=a887dc686dbc48407e54196f84eb2ede). Accessed 19 April 2016.
- Centers for Disease Control and Prevention. National Health Safety Network multidrug-resistant organism and *Clostridium difficile* infection (MDRO/CDI) module (http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf). Accessed 19 April 2016.
- Sailhamer EA, et al. Fulminant *Clostridium difficile* colitis: patterns of care and predictors of mortality. *Archives of Surgery* 2009; **144**: 433–439.
- Debast SB, Bauer MP, Kuijper EJ. Committee. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for *Clostridium difficile* infection (CDI). *Clinical Microbiology and Infection* 2013; **20** (Suppl. 2): 1–26.
- Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development

- and validation. *Journal of Chronic Diseases* 1987; **40**: 373–383.
18. **European Centre for Disease Prevention and Control.** Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals—protocol version 4.3. Stockholm: ECDC; 2012 (<http://ecdc.europa.eu/en/publications/Publications/0512-TED-PPS-HAI-antimicrobial-use-protocol.pdf>). Accessed 19 April 2016.
 19. **Di Bella S, et al.** *Clostridium difficile* infection in Italian urban hospitals: data from 2006 through 2011. *BMC Infectious Diseases* 2013; **13**: 146.
 20. **Baschetti M, et al.** Epidemiology and predictors of recurrence of *Clostridium difficile* infection in a North Italian tertiary care hospital. *Journal of Gastrointestinal and Liver Disease* 2014; **23**: 459–460.
 21. **Evans CT, Safdar N.** Current trends in the epidemiology and outcomes of *Clostridium difficile* infection. *Clinical Infectious Diseases* 2015; **60**: S66–71.
 22. **Honda H, et al.** Incidence and mortality associated with *Clostridium difficile* infection at a Japanese tertiary care center. *Anaerobe* 2014; **25**: 5–10.
 23. **Rodríguez-Pardo D, et al.** Epidemiology of *Clostridium difficile* infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. *Journal of Clinical Microbiology* 2013; **51**: 1465–1473.
 24. **Abou Chakra CN, et al.** Risk factors for recurrence, complications and mortality in *Clostridium difficile* infection: a systematic review. *PLoS ONE* 2014; **9**: e98400.
 25. **Di Bella S, et al.** The protective role of albumin in *Clostridium difficile* infection: a step toward solving the puzzle. *Infection Control and Hospital Epidemiology* 2015; **36**: 1478–1479.
 26. **Eliakim-Raz N, et al.** Predicting *Clostridium difficile* infection in diabetic patients and the effect of metformin therapy: a retrospective, case-control study. *European Journal of Clinical Microbiology and Infectious Diseases* 2015; **34**: 1201–1205.
 27. **Wenisch JM, et al.** Hospital-acquired *Clostridium difficile* infection: determinants for severe disease. *European Journal of Clinical Microbiology and Infectious Diseases* 2012; **31**: 1923–1930.